NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/20/2024
Back to search
Official data from USPTO
CONJUALL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
08/20/2024
Trademark type
Word
Nice classes
5, 42
Filing date
12/27/2021
Registration date
08/20/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/20/2024
Last transaction
08/20/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
03
Owner location
Daejeon, KR
Examiner
FIRST, VIVIAN M
Law office
M50
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
LEGOCHEM BIOSCIENCES, INC.
Representatives
Corey K. Cho Saliwanchik, Lloyd & Eisenschenk, P.A.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicinal preparations for prevention and treatment of canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseasesantibodiesantibody conjugates and active ingredients and antibody conjugates; chemical reagents for medical useespecially chemical reagents for linking molecules for medical use; colostral antibodies and the chemical modifications and conjugates thereof for medical purposes and medical laboratory tests; drug delivery agents consisting of compounds that facilitate delivery of pharmaceuticals for the treatment of canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseases; biological preparations for pharmaceutical purposes for the treatment of canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseases; Chemical preparations for pharmaceutical purposes for the treatment of canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseases; medical pharmaceuticals for use in relation to the treatment of canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseases; medical molecular diagnostic reagents for use in relation to the treatment of canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseases; biopharmaceuticals for use in relation to the treatment of canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseases; pharmaceutical preparations for treatment of rare diseases
Class 42
Scientific study and research in the field(s) of research on the subject of pharmaceuticals; development of pharmaceutical preparations and medicines; medical and pharmaceutical research services; biological research and analysis; chemical research and analysis; biochemical research and analysis; and scientific research in the nature of conducting clinical trials for others
Publications
History of USPTO decisions and trademark events.
28 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
08/20/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/04/2024
PUBO
PUBLISHED FOR OPPOSITION
06/04/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/15/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/02/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/02/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/02/2024
ALIE
ASSIGNED TO LIE
05/02/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
12/12/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/27/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/27/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/27/2023
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
09/14/2023
GNSI
INQUIRY TO SUSPENSION E-MAILED
09/14/2023
CNSI
SUSPENSION INQUIRY WRITTEN
09/14/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
03/17/2023
GNSL
LETTER OF SUSPENSION E-MAILED
03/17/2023
CNSL
SUSPENSION LETTER WRITTEN
03/17/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/22/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/22/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/22/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/29/2022
GNRT
NON-FINAL ACTION E-MAILED
09/29/2022
CNRT
NON-FINAL ACTION WRITTEN
09/29/2022
DOCK
ASSIGNED TO EXAMINER
09/28/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/04/2022
NWAP
NEW APPLICATION ENTERED
12/30/2021
Continuous trademark protection
Get notified about every new filing that threatens CONJUALL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.